Exagen Newsroom

TD Cowen Maintains Exagen(XGN.US) With Buy Rating, Maintains Target Price $7

Futu NewsNov 13 22:31

Exagen's Strategic Advancements and Market Potential Drive Buy Rating Amidst Upcoming ADVISE Test Launch

TipRanksNov 13 22:28

CCORF Maintains Exagen(XGN.US) With Buy Rating, Maintains Target Price $5

Futu NewsNov 13 21:31

BTIG Maintains Exagen(XGN.US) With Buy Rating, Maintains Target Price $5

Futu NewsNov 13 10:31

KeyBanc Maintains Exagen(XGN.US) With Hold Rating

Futu NewsNov 13 09:31

TD Cowen Maintains Exagen(XGN.US) With Buy Rating, Maintains Target Price $7

Futu NewsAug 6 20:35

TD Cowen Maintains Exagen(XGN.US) With Buy Rating, Maintains Target Price $7

Futu NewsAug 6 08:32

Exagen's Strong Q2 Performance and Promising Outlook Merit a Buy Rating

TipRanksAug 6 08:29

Canto Fitzgerald: Maintaining the Exagen (XGN.US) rating, adjusted from an increase to an increase in holdings rating, and the target price was adjusted from $5.00 to $7.00.

Zhitong FinanceMay 14 20:51

Exagen Analyst Ratings

BenzingaMay 14 20:50

Cantor Fitzgerald Maintains Overweight on Exagen, Raises Price Target to $7

BenzingaMay 14 20:50

Exagen's Strong Q1 Earnings and Growth Potential Justify Buy Rating

TipRanksMay 14 19:40

Buy Rating Affirmed for Exagen Amid Strong Sales Growth and Promising Outlook

TipRanksMay 14 07:10

Buy Rating Affirmed for Exagen on Strong Financials and Strategic Growth Initiatives

TipRanksMar 20 18:01

Exagen's Strong Q4 Performance and Positive Outlook Justify Buy Rating

TipRanksMar 19 07:05

Exagen (XGN) Receives a Buy From BTIG

TipRanksJan 2 22:55

Exagen (XGN) Gets a Buy From BTIG

TipRanksDec 31, 2023 18:28

Exagen (XGN) Gets a Buy From Cantor Fitzgerald

TipRanksNov 14, 2023 20:58

Analysts Offer Insights on Healthcare Companies: Exagen (XGN) and Milestone Pharmaceuticals (MIST)

TipRanksNov 14, 2023 10:30

Cantor Fitzgerald Reiterates Overweight on Exagen, Maintains $6 Price Target

BenzingaSep 27, 2023 00:02